Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Next Previous
Trial Profile

The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amisulpride (Primary) ; Haloperidol (Primary) ; Olanzapine (Primary) ; Quetiapine (Primary) ; Ziprasidone (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms EUFEST

    • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 28 Aug 2010 Subgroup analysis presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Dec 2009 Primary endpoints response rate and remission rate on the 'Positive and Negative Syndrome Scale' have been met for amisulpride, olanzapine and ziprasidone versus haloperidol.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top